IR-Med, Inc.

CIK:0001839133|SEC Filings

Interim Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Research and development expenses
Expenses incurred	$ 91	$ 249	$ 155	$ 624
Less- government grants		(155)	(41)	(335)
Research and development expenses, net	91	94	114	289
Marketing expenses	1	28	3	196
General and administrative expenses	194	236	422	531
Total operating loss	286	358	539	1,016
Financial expenses, net	415	8	935	7
Loss for the period	$ 701	$ 366	$ 1,474	$ 1,023
Basic loss per common stock	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.015)
Dilutive loss per common stock	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.015)
Weighted average number of common stock, basic	73,755,083	70,281,511	72,423,280	70,106,284
Weighted average number of common stock, diluted	73,755,083	70,281,511	72,423,280	70,106,284

Interim Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
Cash flows from operating activities
Loss for the period	$ (1,474)	$ (1,023)
Adjustments to reconcile loss for the period to net cash used in operating activities:
Stock based compensation	141	306
Depreciation	7	13
Non-cash financial expenses (income)	933	(3)
Decrease in accounts receivable	49	45
Increase in deferred grant income	173
Decrease in trade and other payables	(10)	(68)
Net cash used in operating activities	(181)	(730)
Cash flows from financing activities
Proceeds from short-term loan	39
Repayment of short-term loan	(39)
Issuance of convertible loans	31
Proceeds from private placement of common stock and warrants. (see also note 4.8)	88	715
Net cash provided by financing activities	119	715
Effect of exchange rate changes on cash and cash equivalents	(4)	1
Net decrease in cash and cash equivalents	(66)	(14)
Cash and cash equivalents as at the beginning of the period	129	767
Cash and cash equivalents as at the end of the period	$ 63	$ 753

Interim Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2025	Dec. 31, 2024
Current assets
Cash and cash equivalents	$ 63	$ 129
Accounts receivable	27	76
Total current assets	90	205
Non- current assets
Long term restricted deposit	11	11
Operating right of use asset	45
Property and equipment, net	29	35
Total non-current assets	85	46
Total assets	175	251
Current liabilities
Trade and other payables	393	388
Deferred grant income	173
Stockholders’ loans	176	157
Convertible loans from related parties	32
Total Current Liabilities	774	545
Non-current liabilities
Long term lease liability	26
Total Non-Current Liabilities	26
Total liabilities	800	545
Commitments and Contingent liabilities
Stockholders’ deficit
Common Stock, par value $0.001 per share, 600,000,000 shares authorized as of June 30, 2025, and December 31, 2024. 77,238,961 and 71,008,144 shares issued as of June 30, 2025, and December 31, 2024, respectively.	77	70
Additional paid-in capital	17,510	16,374
Accumulated deficit	(18,212)	(16,738)
Total Stockholders’ deficit	(625)	(294)
Total liabilities and stockholders’ deficit	$ 175	$ 251